Esophagitis News and Research

RSS

SCYNEXIS announces positive results from first interim efficacy analysis of FURI study

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first interim efficacy analysis of the ongoing FURI study.

1 Feb 2019

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

CDx Diagnostics announces WATS3D data demonstrating crypt dysplasia as risk factor for esophageal cancer

CDx Diagnostics, an innovator in computer synthesized, three dimensional tissue analysis for the early detection and surveillance of Barrett’s esophagus, today announced new data for WATS3D, or Wide Area Transepithelial Sampling with 3D Tissue Analysis, demonstrating the clinical significance of crypt dysplasia as an important risk factor for progression to high-grade esophageal dysplasia or esophageal cancer.

9 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Children with pre-existing allergies should be screened for eosinophilic esophagitis

Children with known skin, food and respiratory allergies should be screened for an emerging, chronic food allergy called eosinophilic esophagitis, a painful inflammation of the esophagus, the food tube between the mouth and stomach.

25 Jun 2018

Advanced lung cancer patients get survival benefit with use of concurrent chemotherapy, proton therapy

For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.

20 Jul 2017

Four-food elimination diet can resolve symptoms of eosinophilic esophagitis in children

Children with eosinophilic esophagitis (EoE) – a chronic inflammatory disease that injures the esophagus – who temporarily eliminated cow's milk, wheat, egg and soy from their diet for eight weeks had their symptoms and esophageal swelling resolve, according to a study published in Clinical Gastroenterology and Hepatology.

27 Jun 2017

Study shows decreased incidence of radiation esophagitis in elderly NSCLC patients

Elderly non-small cell lung cancer (NSCLC) patients undergoing definitive radiation have a lower incidence of esophagitis compared to younger patients and tolerate aggressive standard treatment regimens.

1 Feb 2017

Inflammatory response prompted by secretion of cytokines causes acid reflux damage in GERD patients

The "acid" in "acid reflux" may not be the direct cause of damage to the esophagus as previously suspected, according to researchers at UT Southwestern Medical Center and Dallas VA Medical Center.

18 May 2016

Potential marker of disease activity identified for eosinophilic esophagitis

Researchers have identified a potential marker of disease activity for a severe and often painful food allergic disease called eosinophilic esophagitis (EoE) - possibly sparing children with EoE the discomfort and risk of endoscopic procedures to assess whether their disease is active.

17 May 2016

Non-invasive test to diagnose EoE could replace need for repeated endoscopy

A non-invasive test to diagnose and monitor an inflammatory disease that injures the esophagus - called eosinophilic esophagitis or EoE - would replace the need for repeated endoscopy for a growing number of children and adults with this relatively new condition.

21 Apr 2016

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

EndoGastric Solutions announces assignment of relative value units for new CPT code covering TIF procedure

EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), today announced the Federal Register has posted coding and payment information specific to the new Current Procedural Terminology (CPT)® code covering the Transoral Incisionless Fundoplication (TIF®) procedure.

4 Nov 2015

Scientists elucidate chemical process behind eosinophilic esophagitis

Scientists from the D'Or Institute of Research and Education, the Federal University of Rio de Janeiro and the Yale University School of Medicine have elucidated the chemical process behind a mysterious gastrointestinal disease that is becoming more frequent every day: the eosinophilic esophagitis (EoE), also known as the "asthma of the esophagus".

1 Sep 2015

New guidelines for nutrition of management GI symptoms in children with autism

A new guideline for the nutrition of management gastrointestinal symptoms in children with autism spectrum disorders (ASD) provides a framework for clinicians to navigate frequently seen issues such as food selectivity, alternative diets and nutritional deficits. The expert panel was convened at Marcus Autism Center, an affiliate of Children's Healthcare of Atlanta and the resulting guideline was published online by the Journal of the Academy of Nutrition and Dietetics.

24 Jul 2015

CU research suggests safe, lower-cost way to treat upper gastrointestinal tract problems in children

Physicians at the University of Colorado School of Medicine on the Anschutz Medical Campus have published research that suggests a safe and lower-cost way to diagnose and treat problems in the upper gastrointestinal tract of children.

16 Jul 2015

NGS mutational testing can help detect patients with Barrett's esophagus

Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus. Although periodic surveillance for cancer is recommended for BE patients, these examinations may fail to identify pre-cancerous dysplasia and early cancers.

9 Jun 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Special issue of Gastroenterology highlights how food impacts health and disease

Patients are always interested in understanding what they should eat and how it will impact their health. Physicians are just as interested in advancing their understanding of the major health effects of foods and food-related diseases.

28 Apr 2015

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.

27 Apr 2015